AGPU AGPU Drug Discovery Services — Operating Income

Other segment segments

Similar metrics at other companies

COGTEarly Stage Preclinical And Discovery Programs — Operating Income

$13.98M+42.9%

FLGTLaboratory Services — Operating Income

-$15.22M-407%

DGXDIS business — Operating Income (Loss)

$457M+10.4%

TMOSpecialty Diagnostics — Operating Income (Loss)

$313M+3.0%

TMOLaboratory Products and Biopharma Services — Operating Income (Loss)

$778M+6.4%

COGTResearch And Development Software Facilities And Other Strategic Support — Operating Income

$5.73M+29.6%

Questions, answered.

What is AGPU's drug discovery services — operating income?

AGPU (AGPU) reported drug discovery services — operating income of -$978.38K in Q1 2026.

How has AGPU's drug discovery services — operating income changed year-over-year?

AGPU's drug discovery services — operating income decreased by 12.8% year-over-year, from -$867.42K to -$978.38K.

What does drug discovery services — operating income mean?

Represents the profit or loss generated by the Drug Discovery Services segment after deducting operating expenses from its revenue. This metric measures the core operational performance and profitability of the segment before interest and taxes. It is a primary indicator of whether the segment's business model is self-sustaining.